![Samantha Vieira](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Samantha Vieira active positions
Companies | Position | Start | End |
---|---|---|---|
Anjarium Biosciences AG
![]() Anjarium Biosciences AG BiotechnologyHealth Technology Anjarium Biosciences AG is a Swiss company that focuses on creating a new class of non-viral gene therapies to tackle genetic diseases throughout a patient's lifetime. The company is based in Schlieren, Switzerland. The company's versatile platform leverages breakthrough science and expertise at the interface of genetic medicine, synthetic biology, and nanoparticle engineering to generate a pipeline of advanced gene therapies with unique competitive advantages over current viral-vector based gene therapies. Anjarium's investors include leading international and strategic investors such as Abingworth, Gimv, Omega Funds, Pfizer Ventures, and Surveyor Capital. The company was founded by Joël de Beer, and Stephen Yoo has been the CEO of the company since 2022. | Chief Operating Officer | 11/07/2022 | - |
Career history of Samantha Vieira
Former positions of Samantha Vieira
Companies | Position | Start | End |
---|---|---|---|
BIOGEN INC. | Corporate Officer/Principal | 31/05/2019 | 31/07/2021 |
Statistics
International
United States | 2 |
Switzerland | 2 |
Operational
Chief Operating Officer | 1 |
Corporate Officer/Principal | 1 |
Sectoral
Health Technology | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
BIOGEN INC. | Health Technology |
Private companies | 1 |
---|---|
Anjarium Biosciences AG
![]() Anjarium Biosciences AG BiotechnologyHealth Technology Anjarium Biosciences AG is a Swiss company that focuses on creating a new class of non-viral gene therapies to tackle genetic diseases throughout a patient's lifetime. The company is based in Schlieren, Switzerland. The company's versatile platform leverages breakthrough science and expertise at the interface of genetic medicine, synthetic biology, and nanoparticle engineering to generate a pipeline of advanced gene therapies with unique competitive advantages over current viral-vector based gene therapies. Anjarium's investors include leading international and strategic investors such as Abingworth, Gimv, Omega Funds, Pfizer Ventures, and Surveyor Capital. The company was founded by Joël de Beer, and Stephen Yoo has been the CEO of the company since 2022. | Health Technology |
- Stock Market
- Insiders
- Samantha Vieira
- Experience